Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) stock jumped 4.54% on Friday to $16.12 against a previous-day closing price of $15.42. With 0.6 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.76 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $16.21 whereas the lowest price it dropped to was $15.42. The 52-week range on ICPT shows that it touched its highest point at $21.25 and its lowest point at $10.81 during that stretch. It currently has a 1-year price target of $22.71. Beta for the stock currently stands at 1.20.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ICPT was down-trending over the past week, with a drop of -2.18%, but this was up by 37.31% over a month. Three-month performance surged to 24.86% while six-month performance rose 11.17%. The stock lost -7.62% in the past year, while it has gained 30.32% so far this year. A look at the trailing 12-month EPS for ICPT yields -6.07 with Next year EPS estimates of -2.61. For the next quarter, that number is -0.38. This implies an EPS growth rate of 65.60% for this year and -148.30% for next year. EPS is expected to decline by -8.89% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 29.70%.
Float and Shares Shorts:
At present, 41.42 million ICPT shares are outstanding with a float of 40.10 million shares on hand for trading. On Oct 13, 2022, short shares totaled 4.02 million, which was 9.78% higher than short shares on Sep 14, 2022. In addition to Mr. Jerome B. Durso as the firm’s Pres, CEO & Director, Mr. Andrew Saik serves as its Chief Financial Officer.
Through their ownership of 78.31% of ICPT’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 37.94% of ICPT, in contrast to 31.07% held by mutual funds. Shares owned by individuals account for 19.65%. As the largest shareholder in ICPT with 7.37% of the stake, SSgA Funds Management, Inc. holds 3,051,584 shares worth 3,051,584. A second-largest stockholder of ICPT, The Vanguard Group, Inc., holds 2,644,516 shares, controlling over 6.39% of the firm’s shares. Point72 Asset Management LP is the third largest shareholder in ICPT, holding 2,033,444 shares or 4.91% stake. With a 6.30% stake in ICPT, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 2,608,970 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.71% of ICPT stock, is the second-largest Mutual Fund holder. It holds 1,123,441 shares valued at 13.9 million. Vanguard Strategic Equity Fund holds 2.11% of the stake in ICPT, owning 873,871 shares worth 10.81 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ICPT since 16 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 9 believe that the stock is worth HOLDING, 2 give it an OVERWEIGHT rating, and 1 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ICPT analysts setting a high price target of $49.00 and a low target of $11.00, the average target price over the next 12 months is $22.71. Based on these targets, ICPT could surge 203.97% to reach the target high and fall by -31.76% to reach the target low. Reaching the average price target will result in a growth of 40.88% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. ICPT will report FY 2022 earnings on 02/28/2024. Analysts have provided yearly estimates in a range of $7.40 being high and $3.95 being low. For ICPT, this leads to a yearly average estimate of $6.13. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Intercept Pharmaceuticals Inc. surprised analysts by $8.65 when it reported $7.80 EPS against a consensus estimate of -$0.85. The surprise factor in the prior quarter was $0.22. Based on analyst estimates, the high estimate for the next quarter is $0.40 and the low estimate is -$1.02. The average estimate for the next quarter is thus -$0.36.
Summary of Insider Activity:
Insiders traded ICPT stock several times over the past three months with 0 Buys and 4 Sells. In these transactions, 0 shares were bought while 3,643 shares were sold. The number of buy transactions has increased to 15 while that of sell transactions has risen to 20 over the past year. The total number of shares bought during that period was 143,722 while 23,288 shares were sold.